Recently, it was reported that the mammalian target of rapamycin (MTOR, a serine- threonine kinase of the phosphatidylinositol (PI) kinase-related protein kinase family [7]) is activated in various carcinoma cells, including breast cancer [8], ovarian cancer [9], and HCC [10]. This evidence concerns the gene MTOR and carcinoma.